HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody
Wei Wang(Nanfang Hospital), Saburo Sone(Io Therapeutics (United States)), Kazuo Minakuchi(Osaka City University), Yasuhiko Nishioka(Tokushima University), Ali Jalili(Kurdistan University of Medical Sciences), Shuji Ozaki(Tokushima Prefectural Central Hospital), Shinji Abe(Tokushima University), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Masatoshi Kishuku(Tokushima University Hospital), Toshio Matsumoto(Brazilian Society of Speech)
Cited by 64
Related Papers
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
|Leukemia|2017|356
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
|Molecular Cancer|2019|316
A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density
|Journal of Bone and Mineral Research|2014|291